LongeVC’s Q3 & Q4 2024: Investments and Portfolio Updates

As 2024 comes to a close, LongeVC continues to support the growth of biotech and longevity innovation—both through new investments and the progress of its existing portfolio companies. Here’s a look at the latest milestones from the second half of the year:

Turn Bio: Expanding mRNA medicine with a $300M+ licensing deal

Turn Bio secured a global licensing agreement with HanAll Biopharma to develop treatments for age-related eye and ear conditions. This $300M+ deal expands Turn Bio’s mRNA medicine platform and accelerates the development of new therapies. Read more here.

Longenesis: Supernova Challenge winner and new strategic partnerships

Longenesis won the Supernova Challenge 2.0 at Expand North Star 2024, securing a $100,000 prize. The company also established a strategic partnership to advance its regenerative medicine initiatives, further strengthening its clinical innovation pipeline. More details here.

Glyphic Bio: LongeVC invests in next-generation protein sequencing

LongeVC backed Glyphic Bio in its latest funding round to support the development of next-generation protein sequencing technology. This breakthrough has the potential to redefine proteomics and unlock new opportunities in drug discovery and personalized medicine. LongeVC’s announcement here.

Proton Intelligence: LongeVC invests in advanced diagnostics

LongeVC invested in Proton Intelligence as part of its $6.95M seed round, supporting the development of its continuous potassium monitoring platform. This technology aims to improve the management of cardio-kidney-metabolic diseases by providing real-time, precise diagnostics, addressing a major gap in early detection and patient monitoring. More details here.

LongeVC remains focused on backing companies that push the boundaries of biotech and longevity. Whether through new investments or continued support of its portfolio, we are committed to driving real innovation in healthcare and life sciences.

For more information, contact us at hq@longevc.com and follow us on LinkedIn.